{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Amarikwa L"],"funding":["NEI NIH HHS","National Institute of Health"],"pagination":["858-864"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10211488"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["108(4)"],"pubmed_abstract":["<h4>Context</h4>Graves orbitopathy (GO) or thyroid eye disease is a potentially sight-threatening and disfiguring autoimmune disease. Teprotumumab is a monoclonal antibody against the insulin-like growth factor-I receptor that was recently approved for GO treatment. Hyperglycemia is a recognized adverse event of teprotumumab, occurring in 10% of patients in 2 recent randomized controlled trials.<h4>Objective</h4>Our study aimed to report the incidence, severity, management, and longitudinal glycemic changes in patients treated with teprotumumab in an academic practice cohort.<h4>Methods</h4>This longitudinal, observational study included all consecutive patients treated with teprotumumab between March 2020 and May 2022 at 1 institution. Hemoglobin A1c (HbA1c) was measured every 3 months.<h"],"journal":["The Journal of clinical endocrinology and metabolism"],"pubmed_title":["Teprotumumab-Related Hyperglycemia."],"pmcid":["PMC10211488"],"funding_grant_id":["P30 EY026877","NIH P30 026877"],"pubmed_authors":["Kim SH","Kossler AL","Dosiou C","Mohamed A","Amarikwa L"],"additional_accession":[]},"is_claimable":false,"name":"Teprotumumab-Related Hyperglycemia.","description":"<h4>Context</h4>Graves orbitopathy (GO) or thyroid eye disease is a potentially sight-threatening and disfiguring autoimmune disease. Teprotumumab is a monoclonal antibody against the insulin-like growth factor-I receptor that was recently approved for GO treatment. Hyperglycemia is a recognized adverse event of teprotumumab, occurring in 10% of patients in 2 recent randomized controlled trials.<h4>Objective</h4>Our study aimed to report the incidence, severity, management, and longitudinal glycemic changes in patients treated with teprotumumab in an academic practice cohort.<h4>Methods</h4>This longitudinal, observational study included all consecutive patients treated with teprotumumab between March 2020 and May 2022 at 1 institution. Hemoglobin A1c (HbA1c) was measured every 3 months.<h","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-05-29T20:47:25.989Z","creation":"2025-05-29T20:47:25.989Z"},"accession":"S-EPMC10211488","cross_references":{"pubmed":["36300333"],"doi":["10.1210/clinem/dgac627"]}}